Last update 08 May 2025

Human Allogeneic Mesenchymal Bone Marrow Cells(Medstar Health Research Institute)

Overview

Basic Info

Drug Type
Mesenchymal stem cell therapy
Synonyms
aMBMC(Medstar Health Research Institute)
Target-
Action-
Mechanism
Stem cell replacements
Therapeutic Areas
Cardiovascular Diseases
Active Indication-
Inactive Indication
Myocardial IschemiaNon-ischemic Cardiomyopathy
Originator Organization
MedStar Research Institute
Active Organization-
Inactive Organization
MedStar Research Institute
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Human Allogeneic Mesenchymal Bone Marrow Cells(Medstar Health Research Institute)
NCT03925324
/ TerminatedPhase 2IIT
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device
100 Clinical Results associated with Human Allogeneic Mesenchymal Bone Marrow Cells(Medstar Health Research Institute)
Login to view more data
100 Translational Medicine associated with Human Allogeneic Mesenchymal Bone Marrow Cells(Medstar Health Research Institute)
Login to view more data
100 Patents (Medical) associated with Human Allogeneic Mesenchymal Bone Marrow Cells(Medstar Health Research Institute)
Login to view more data
100 Deals associated with Human Allogeneic Mesenchymal Bone Marrow Cells(Medstar Health Research Institute)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myocardial IschemiaPhase 2
United States
MedStar Research Institute
03 May 2019
Non-ischemic CardiomyopathyPhase 2
United States
MedStar Research Institute
03 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03925324 (STEM-VAD, CTgov)
Phase 2
Non-ischemic Cardiomyopathy | Myocardial Ischemia
4
(Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC))
(ozddsvksej) = fgoyehqtsi vcxjuhrqmj (xmrjmfcvyz, skkahdrdak - orwibzvxvs)
View more
-
02 Feb 2022
Placebo
(Placebo)
(ozddsvksej) = qutlfkguui vcxjuhrqmj (xmrjmfcvyz, pyeupyfqyn - fzswoxcokp)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free